首页> 外文OA文献 >Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

【2h】

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

机译：非小细胞肺癌ALK易位患者对ALK抑制剂（Crizotinib，PF02341066）的快速而戏剧性的影像学和临床反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ou Sai-Hong Ignatius; Bazhenova Lyudmila; Camidge D. Ross; Solomon Benjamin J.; Herman June; Kain Tatiana; Bang Yung-Jue; Kwak Eunice L.; Shaw Alice T.; Salgia Ravi; Maki Robert G.; Clark Jeffrey W.; Wilner Keith D.; Iafrate A. John;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. [J] . Ou SH, Bazhenova L, Camidge DR, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2010,第12期

机译：非小细胞肺癌ALK易位阳性患者对ALK抑制剂（crizotinib，PF02341066）的快速而显着的放射学和临床反应。
2. Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. [J] . Iafrate AJ Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2011,第5期

机译：非小细胞肺癌De Novo MET扩增患者Crizotinib（PF02341066），间充质-上皮双重转化（MET）和间变性淋巴瘤激酶（ALK）抑制剂的活性。
3. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer [J] . Anne McLeer-Florin, Michael Duruisseaux, Julian Pinsolle, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：ALK融合变体检测通过靶向RNA-NEXT GENAY测序和临床反应在ALK阳性非小细胞肺癌中对CRIZOTINIB进行临床反应
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK [O] . Yunguang Sun, Kamila A. Nowak, Nicholas G. Zaorsky, -1

机译：ALK抑制剂PF02341066（Croizotinib）增加了表达EML4-ALK的非小细胞肺癌中的辐射的敏感性
7. Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification [O] . Ou Sai-Hong Ignatius, Kwak Eunice L., Siwak-Tapp Christina, 2011

机译：非小细胞肺癌De Novo MET扩增患者Crizotinib（PF02341066），间充质-上皮双重转化（MET）和间变性淋巴瘤激酶（ALK）抑制剂的活性

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅